H
Loading...
Loading...
CDC PLACES (2023, crude) estimates 12% of adults in Chicago have diagnosed diabetes — about even with the U.S. 12% figure. Census population 2,693,976. Illinois Medicare wound biologics: National Government Services (NGS) (J6). Hawk Medical is a national HCT/P 361 and wound-care distributor serving licensed Chicago clinics — not a walk-in office.
Written for licensed providers. Reviewed by Joe Bradley, Founder & CEO. Content version 2026-09-18. Hawk Medical ships nationwide — this is not a Chicago storefront.
361 HCT/P Compliant Tissue Products in Chicago, IL for clinics & physicians. Exclusively 361 HCT/P complia… Compliance support & pricing — contact Hawk Medical.
Joe Bradley will tell you the same thing he tells his own staff: epidemiology first, then MAC, then SKU. CDC PLACES (2023, crude) estimates 12% of adults in Chicago have diagnosed diabetes — about even with the U.S. 12% figure. 13.6% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. Then we pick 361 hctp compliant products against that mix.
National 361 HCT/P Compliant Tissue Products notes (how the product actually works)J6 reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Chicago is 12% or not. PLACES is planning data. The LCD is the claim.
Vendor consolidation is boring on purpose: one account, IFUs filed, J6 articles mapped. 13.6% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. Pricing scripts have to match that mix. We will help write them. We will not book your patients.
CDC PLACES (2023, crude prevalence) estimates 12% of adults — about even with the U.S. 12% figure. Obesity is 32.6%; arthritis is 19.6%. That is place-level BRFSS modeling, not a clinic census and not a Chicago trial.
It is the Census city-proper count — useful as scale for a city of 1M+. It is not a count of orthopedic groups, wound centers, or competitors. Underwrite the program against your referral sources, not against the skyline.
Use the contact form or book a 15-minute call with Joe Bradley. Bring specialty, monthly wound or joint volume, and whether you bill J6 FFS, Advantage, workers’ comp, or cash-pay.
No. Hawk Medical does not distribute products as “stem cell therapy.” HCT/P 361 allografts are regulated under 21 CFR 1271 for homologous use and minimal manipulation. PRP is autologous. Marketing that blurs those lanes is a compliance problem in every state, including Illinois.
If you operate in Illinois and another MAC state, say it on the first call. J6 will not port 1:1. We would rather split utilization than watch a sister clinic copy Chicago tickets into the wrong jurisdiction.
Contact us to learn how Hawk Medical supports practices in Chicago, IL.
Hawk Medical is a national distributor. Joe Bradley’s clinic uses the same product classes. What is local for Chicago is J6 geography and published epidemiology — not a street address.
CDC PLACES 2023 crude rate for Chicago — about even with the U.S. 12% figure. Planning input, not an outcomes claim.
Illinois Part B wound biologics follow this contractor (siblings: MN, WI). We train to the articles. We do not write coverage.
PLACES crude adult arthritis in Chicago. Useful for joint-program math; still needs a diagnosis and privileging.
No Chicago storefront. Joe Bradley is an active practice owner. 361 hctp compliant products stays in its regulatory lane — not “FDA-approved stem cell therapy.”
Experience the difference of working with a distributor who understands your practice because we operate one ourselves.